ENTITY
Immunotech Biopharm

Immunotech Biopharm (6978 HK)

16
Analysis
Health Care • China
Immunotech Biopharm is a cellular immunotherapy biopharmaceutical company in China, focused on the research, development, and commercialization of T-cell immunotherapy for cancer treatments. Its key products include EAL (Expanded Activated Lymphocytes), CAR-T cell series, and TCR-T cell series products. The company is headquartered in Beijing, China, and was founded in 2006.
more
bearish•Immunotech Biopharm
•23 Jun 2020 15:57

Immunotech Biopharm (ę°øę³°ē”Ÿē‰©) IPO: Behind the Curve in Cell Therapy

Immunotech Biopharma, a cell therapy focused healthcare company, launched book building to raise up to USD 142 million to list in Hong Kong. In our...

Logo
845 Views
Share
bullish•Legend Biotech Corp
•19 May 2020 12:14

Legend Biotech (ä¼ å„‡ē”Ÿē‰©) Pre-IPO: All-Stars Except for the Small Indication

Legend Biotech, a subsidiary of Hong Kong-listed GenScript, is planning to raise up to USD 300 million via an IPO. The company has a strong focus...

Logo
354 Views
Share
bullish•AllHome Corp
•07 Sep 2019 14:15

ECM Weekly (7 Sep 2019) - China Merchants Comm REIT, Immunotech Bio, Bank of Guizhou, XD, Huize

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
bearish•Immunotech Biopharm
•05 Sep 2019 16:48

Immunotech Biopharm (ę°øę³°ē”Ÿē‰©) IPO: Challenges for Cellular Immunotherapies

Immunotech Biopharma, a leading cellular immunotherapy company in China, aims to raise USD 100 to 200 million via a Hong Kong listing. In this...

Logo
997 Views
Share
x